Coventry Challenges Allegations from Abacus Global Management Amid Lawsuit
In a recent turn of events, Coventry, recognized as the pioneer and leader in the secondary market for life insurance, has issued a strong rebuttal to the unfounded lawsuit initiated by Abacus Global Management, Inc. This legal challenge has raised eyebrows within the industry, and Coventry is taking a firm stance, asserting the meritless nature of Abacus's claims.
On July 2, 2025, Coventry responded publicly, outlining the concerns regarding Abacus’s legal arguments. Alan Buerger, the Chairman of Coventry, characterized Abacus’s lawsuit as a diversionary tactic, designed frankly to delay accountability while shifting focus away from pressing internal issues that Abacus currently faces. Coventry maintains that Abacus's partner, Lapetus, systematically underestimates life expectancies, a practice that directly jeopardizes investor returns. Detailed analytical studies available through Coventry have reinforced this viewpoint, offering empirical backing to their claims.
Abacus's complaint asserts that their policy valuations do not rely on Lapetus's life expectancy figures. Moreover, they claim to utilize market-based fair value accounting instead of life expectancy models. However, Coventry finds these statements contradictory to Abacus’s prior communications, particularly in their SEC filings. The filings outlined that Abacus employs various inputs to determine fair value metrics for their policies, which explicitly includes life expectancy reports generated by Lapetus, where Abacus holds a minority stake.
Further complicating Abacus's argument, documents related to a newly offered investment fund by Abacus disclose that they will indeed utilize Lapetus as their primary life expectancy provider, indicating a clear reliance on the very estimates they attempt to refute in their legal complaints. The assertions made by Abacus appear to lack the consistency required for credibility, as they continue to promote Lapetus in their valuation protocols, fundamentally undermining their own claims.
Of particular note is Abacus’s assertion of never having encountered Morpheus Research prior to its critical report on the company. Coventry firmly states that they were unaware of Morpheus Research prior to this incident. With confidence in the robustness and reputation of their position in the market, Coventry underscores that Abacus's lawsuit lacks substantial merit.
For over two decades, Coventry has been at the forefront of transforming the established practices within the life insurance sector. The company’s unwavering commitment to consumer rights is reflected in its significant contributions to policyholders, with more than $6 billion delivered to those looking to sell their unneeded life insurance policies. This history of leadership reaffirms Coventry's dedication to enhancing industry standards and amplifying consumer options.
For more information about Coventry and its market positioning, including access to detailed research supporting its claims about life expectancy and investor returns, visit their official website at Coventry.com. As this legal situation develops, it will undoubtedly attract the attention of industry leaders and stakeholders watching closely how this lawsuit could affect the life insurance secondary market landscape.
On July 2, 2025, Coventry responded publicly, outlining the concerns regarding Abacus’s legal arguments. Alan Buerger, the Chairman of Coventry, characterized Abacus’s lawsuit as a diversionary tactic, designed frankly to delay accountability while shifting focus away from pressing internal issues that Abacus currently faces. Coventry maintains that Abacus's partner, Lapetus, systematically underestimates life expectancies, a practice that directly jeopardizes investor returns. Detailed analytical studies available through Coventry have reinforced this viewpoint, offering empirical backing to their claims.
Abacus's complaint asserts that their policy valuations do not rely on Lapetus's life expectancy figures. Moreover, they claim to utilize market-based fair value accounting instead of life expectancy models. However, Coventry finds these statements contradictory to Abacus’s prior communications, particularly in their SEC filings. The filings outlined that Abacus employs various inputs to determine fair value metrics for their policies, which explicitly includes life expectancy reports generated by Lapetus, where Abacus holds a minority stake.
Further complicating Abacus's argument, documents related to a newly offered investment fund by Abacus disclose that they will indeed utilize Lapetus as their primary life expectancy provider, indicating a clear reliance on the very estimates they attempt to refute in their legal complaints. The assertions made by Abacus appear to lack the consistency required for credibility, as they continue to promote Lapetus in their valuation protocols, fundamentally undermining their own claims.
Of particular note is Abacus’s assertion of never having encountered Morpheus Research prior to its critical report on the company. Coventry firmly states that they were unaware of Morpheus Research prior to this incident. With confidence in the robustness and reputation of their position in the market, Coventry underscores that Abacus's lawsuit lacks substantial merit.
For over two decades, Coventry has been at the forefront of transforming the established practices within the life insurance sector. The company’s unwavering commitment to consumer rights is reflected in its significant contributions to policyholders, with more than $6 billion delivered to those looking to sell their unneeded life insurance policies. This history of leadership reaffirms Coventry's dedication to enhancing industry standards and amplifying consumer options.
For more information about Coventry and its market positioning, including access to detailed research supporting its claims about life expectancy and investor returns, visit their official website at Coventry.com. As this legal situation develops, it will undoubtedly attract the attention of industry leaders and stakeholders watching closely how this lawsuit could affect the life insurance secondary market landscape.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.